Literature DB >> 9536001

Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding.

N Mohell.   

Abstract

In this study, the ligand-receptor-G protein interactions of the dopamine D3 receptor expressed in Chinese hamster ovary cells were investigated using guanosine 5'-[gamma-thio]triphosphate-[35S] ([35S]GTPgammaS) and receptor binding experiments. Dopamine stimulated the [35S]GTPgammaS binding in a guanine nucleotide, magnesium and sodium-dependent manner. Dopamine and quinpirole produced maximal stimulation of the [35S]GTPgammaS binding whereas (+)-7-OH-DPAT and (-)-3-PPP were partial agonists. Interestingly, several compounds previously classified as D2 receptor antagonists behaved as inverse agonists at the D3 receptor, i.e., they inhibited the basal [35S]GTPgammaS binding in a dose dependent fashion. Haloperidol, (+)-UH-232, (+)-AJ-76 and raclopride were full inverse agonists but clozapine was a partial inverse agonist. Pertussis toxin treatment abolished the D3 receptor-mediated agonist as well as inverse agonist responses, indicating the involvement of Gi/Go proteins in both processes. According to the ternary complex model, agonists should bind with higher affinity to the G protein coupled receptor (RG) and thereby shift the equilibrium from free receptor (R) toward RG, which produces a biological response. However, an inverse agonist should bind with higher affinity to R than to RG and thereby inhibit the basal activity of the cell. We found that the high affinity agonist binding site (RG) was abolished by pertussis toxin treatment of the cells. However, the inverse agonists bound with the same affinity to untreated and pertussis toxin treated D3 receptor membranes. Thus, we found no evidence for the hypothesis that inverse agonists would shift the equilibrium from RG toward R by binding with higher affinity to R than to RG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536001

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization.

Authors:  Johan P Rung; Emilia Rung; Lisa Helgeson; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2008-03-20       Impact factor: 3.575

2.  Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Authors:  Amarendra N Singh; Cia Barlas; Huma Saeedi; Ram K Mishra
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

3.  Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.

Authors:  C L Neilan; H Akil; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.

Authors:  Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

5.  Inverse agonism and its therapeutic significance.

Authors:  Gurudas Khilnani; Ajeet Kumar Khilnani
Journal:  Indian J Pharmacol       Date:  2011-09       Impact factor: 1.200

Review 6.  Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.

Authors:  Claudia Rangel-Barajas; George V Rebec
Journal:  J Huntingtons Dis       Date:  2016-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.